Short Interest in Synaptogenix, Inc. (NASDAQ:SNPX) Drops By 37.8%

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 12,000 shares, a decrease of 37.8% from the March 15th total of 19,300 shares. Based on an average daily trading volume, of 12,200 shares, the short-interest ratio is presently 1.0 days. Approximately 0.9% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC acquired a new position in Synaptogenix, Inc. (NASDAQ:SNPX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.80% of Synaptogenix as of its most recent SEC filing. Hedge funds and other institutional investors own 10.34% of the company’s stock.

Synaptogenix Stock Down 5.2 %

NASDAQ SNPX traded down $0.12 on Friday, reaching $2.12. The company had a trading volume of 2,130 shares, compared to its average volume of 26,546. Synaptogenix has a 52 week low of $1.84 and a 52 week high of $5.38. The stock’s 50 day moving average is $2.61 and its 200-day moving average is $2.92. The stock has a market cap of $2.94 million, a price-to-earnings ratio of -0.20 and a beta of 1.07.

Synaptogenix (NASDAQ:SNPX) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($4.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.06) by ($2.30).

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.